Soluble Fcgamma receptors have been identified in biological fluids of
mice and humans. They are produced either by alternative splicing of
the exon encoding the transmembmne region of the receptor (FcgammaRII)
or by proteolytic cleavage at the cell membrane (FcgammaRII and Fcgam
maRIII). They inhibit B cell proliferation and immunoglobulin producti
on. Their concentrations in plasma seem to be modified during the deve
lopment of certain diseases, as for instance in multiple myeloma, wher
e plasma concentrations of soluble FcgammaRIII are correlated with the
stage of the disease.